A previous study of Parkinson’s disease in patients with co-morbid inflammatory bowel disease reported that TNF blocking agents were associated with decreased incidence of Parkinson’s disease[43], while therapeutic benefit was reported earlier for reducing risk of major depression in a pivotal, Phase 3 clinical trial of etanercept for the treatment of psoriasis [44]. This evidence concerns the gene TNF and major depressive disorder.